Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-02
2011-08-02
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S250000
Reexamination Certificate
active
07989464
ABSTRACT:
In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J4, X, and R1-R5are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.
REFERENCES:
patent: 6232320 (2001-05-01), Stewart et al.
patent: 7485648 (2009-02-01), Matasi et al.
patent: 2002/0151544 (2002-10-01), Hayakawa et al.
patent: 2006/0167029 (2006-07-01), Matasi et al.
patent: 2006/0189639 (2006-08-01), Stewart et al.
patent: 2009/0082336 (2009-03-01), Matasi et al.
patent: WO 01/32632 (2001-05-01), None
patent: WO 02/062803 (2002-08-01), None
patent: WO 2006/002051 (2006-01-01), None
patent: WO 2006/081072 (2006-08-01), None
Kadushkin, et al., DMF Diethyl Acetyl as a One-carbon Component in the Synthesis of Isomeric Pyridothienopyrimidines, Khimiko-Farmatsevticheskii Zhurnal, 27(3), 40-3 (1993).
Bhave et al., “Peripheral group I metabotropic glutamate receptors modulate nociception in mice”, Nature Neuroscience, vol. 4, pp. 417-423 (2001).
Bousquet et al., “Synthesis and Pharmacological Activity of 3-Substituted Pyrido(3', 2':4,5)Thieno(3,2-d)Pyrimidin-4(3H)-Ones”, Institute of Pharmaceutical and Toxicological Chemistry, vol. 39, No. 2, pp. 110-119 (1984).
Chang et al., “Analgesic activity of metabotropic glutamate receptor 1 antagonists on spontaneous post-operative pain in rats”, European Journal of Pharmacology, vol. 580, pp. 314-321 (1984).
Dolan et al., “Behavioral evidence supporting a differential role for spinal group I and II metabotropic glutamate receptors in inflammatory hyperalgesia in sheep”, Neuropharmacology, (2002) vol. 43, pp. 319-326.
Dolan et al., “Up-regulation of metabotropic glutamate receptor subtypes 3 and 5 in spinal cord in a clinical model of persistent inflammation and hyperalgesia”, Pain, vol. 106, pp. 501-512 (2003).
El-Kouhen et al., “Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A-841720, a novel non-competitive mGluR1 receptor antagonist”, British Journal of Pharmacology, vol. 149, pp. 761-774 (2006).
Fisher et al., “Hyperalgesia and allodynia induced by intrathecal (RS)-dihydroxyphenylglycine in rats”, NeuroReport, vol. 9, pp. 1169-1172 (1998).
Fundytus et al., “Antisense oligonucleotide knockdown of mGluR1alleviates hyperalgesia and allodynia associated with chronic inflammation”, Pharmacology, Biochemistry and Behavior, vol. 73, pp. 401-140 (2002).
Fundytus et al., “In vivo antinociceptive activity of anti-rate mGluR1and mGluR5antibodies in rats”, NeuroReport, vol. 9, pp. 731-735 (1998).
Fundytus et al., “Knockdown of spinal metabotropic glutamate receptor 1 (mGluR1) alleviates pain and restores opioid efficacy after nerve injury in rats”, British Journal of Pharmacology, vol. 132, pp. 354-367 (2001).
Kadushkin et al, “DMF diethyl acetal as a one-carbon component in the synthesis of isomeric pyridothienopyrimidines,” Khimiko-Farmatsevticheskii Zhurnal, vol. 27(3), pp. 40-43 (1993) + English Abstract.
Kamble et al, “Synthesis of some new heterocyclic systems bearing (3H)-benzofuropyrimidin-4-one-3-yl moiety as antibacterial agents,” Indian Journal of Heterocyclic Chemistry, vol. 9(1), pp. 23-26 (Sep. 1999).
Mahajan et al., “Studies in benzofurans: Part VIII. Synthesis of some 3-N-aryl-, 3-N-alkyl- and 3-amino-3, 4-dihydro-4-oxobenzofuro[3,2-d]pyrimidines”, Indian Journal of Chemistry, Section B: Organic Chemistry including Medicinal Chemistry, vol. 19B(5), pp. 402-404 (1980).
Merour, “Specific synthesis of pyrimidines. Concurrent formation of pyrimidines and triazepines,” Journal of Heterocyclic Chemistry, vol. 19(6), pp. 1425-1431 (1982) + English Abstract.
Mills and Hulsebosch, “Increased expression of metabotropic glutamate receptor subtype 1 on spinothalamic tract neurons following spinal cord injury in the rat”, Neuroscience Letters vol. 319, pp. 59-62 (2002).
More et al., “Comparison of the mGluR1 antagonist A-841720 in rat models of pain and cognition”, Behavioral Pharmacology, vol. 18, pp. 273-281 (2007).
Neugebauer et al., “Peripheral metabotropic glutamate receptors: fight the pain where it hurts”, Trends in Neurosciences, vol. 24, pp. 550-552 (2001).
Neugebauer et al., “Role of Metabotropic Glutamate Receptor Subtype mGluR1 in Brief Nociception and Central Sensitization of Primate STT Cells”, Journal of Neurophysiology, vol. 82, pp. 272-282 (1999).
Russo et al, “New nitrogenous polycyclic systems: Synthesis and pharmacological properties of benzofuro and thienothiadiazolopyrimidine derivatives”, Farmaco, Edizione Scientifica, vol. 38(10), pp. 762-764 (1983) + English Abstract.
West et al., Solid State Chemistry and Its Applications, Wiley, New York, 358 (1988).
Young et al., “Antisense Ablation of Type I Metabotropic Glutamate Receptor mGluR1Inhibits Spinal Nociceptive Transmission”, The Journal of Neuroscience, vol. 18, pp. 10180-10188 (1998).
Young et al., “Behavioural and electrophysiological evidence supporting a role for group I metabotropic glutamate receptors in the mediation of nociceptive inputs to the rat spinal cord”, vol. 777, pp. 161-169 (1997).
Young et al., “Evidence for a Role of Metabotropic Glutamate Receptors in Sustained Nociceptive Inputs to Rat Dorsal Horn Neurons”, Neuropharmacology, vol. 33, pp. 141-144 (1994).
Zheng et al., “Correlation between brain/plasma ratios and efficacy in neuropathic pain models of selective metabotropic glutamate receptor 1 antagonists”, Bioorganic & Medicinal Chemistry Letters, vol. 16, pp. 4936-4940 (2006).
Zheng et al., “Structure—Activity Relationship of Triazafluorenone Derivatives as Potent and Selective mGluR1 Antagonists”, Journal of Medicinal Chemistry, American Chemical Society, Washington, US, vol. 48, pp. 7374-7388 (2005).
International Search Report for International Application No. PCT/US2005/020972, mailed Oct. 26, 2005 (5 pages).
International Search Report for International Application No. PCT/US2006/046943, mailed Aug. 30, 2007 (5 pages).
Burnett Duane A.
Domalski Martin S.
Korakas Peter
Matasi Julius J.
Qiang Li
Leeser Erich
MacMillan Keith D.
Schering Corporation
Todaro John C.
Vidale Kenrick L.
LandOfFree
mGluR1 antagonists as therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with mGluR1 antagonists as therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and mGluR1 antagonists as therapeutic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2698818